ALK and non-small cell lung carcinoma: OTX015 appears to be a promising therapeutic strategy for EML4-ALK positive patients as well as KRAS-mutant NSCLC patients with wildtype LKB1, whereas EGFR mutations did not correlate with the outcome of BET inhibition.